Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S41-5. doi: 10.1097/PCC.0b013e3181d10845.

Prostacyclin in the intensive care setting.

Author information

1
Department of Pediatrics, University of Colorado Denver School of Medicine, The Children's Hospital, Aurora, CO, USA. ivy.dunbar@tchden.org

Abstract

The prostacyclins-prostanoids were one of the first medications used to treat pulmonary arterial hypertension (PAH). Three prostanoids have been developed to treat PAH: epoprostenol, treprostinil, and iloprost. In the acute setting, experience is growing, using the inhaled forms of these three medications. Inhalation may improve ventilation/perfusion matching, whereas in the intravenous form these medications may cause nonselective pulmonary vasodilation and may worsen ventilation/perfusion matching. Currently, there are no universal recommendations for dosing delivery of inhaled prostanoids to intubated patients in the intensive care unit setting.

PMID:
20216163
PMCID:
PMC3116926
DOI:
10.1097/PCC.0b013e3181d10845
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Support Center